Hyperhomocysteinaemia is an Independent Risk Factor for Peripheral Arterial Disease in a Chinese Han Population

Overview

Journal Atherosclerosis

Publisher Elsevier

Specialty Cardiology & Vascular Diseases

Date 2017 Jun 27

PMID 28651188

Citations 15

Authors

Dan Rong

Jie Liu

Xin Jia

Daniah Al-Nafisee

Senhao Jia

Guoyi Sun

Yue Li

Weihang Lu

Haifeng Li

Hongpeng Zhang

Xiaohui Ma

Jiang Xiong

Xiaoping Liu

Raouf A Khalil

Wei Guo

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Hyperhomocysteineamia (HHcy) has long been suggested as a risk factor for atherosclerosis. However, the association between HHcy and peripheral arterial disease (PAD) is still controversial. There is a lack of research on this topic in the Chinese population. This study aims to provide further results.

Methods: 240 PAD patients and 240 control subjects were evaluated for both serum total homocysteine levels and ankle brachial indexes (ABIs). Multivariable logistic regression models were used to estimate the association between HHcy and the risk of developing PAD. Interaction and stratified analyses were conducted according to age, sex, smoking status, drinking status, and histories of chronic disease.

Results: The multivariate logistic regression analyses revealed that the risk of PAD was significantly associated with serum homocysteine levels. The interaction analysis showed no interactive role in the association between HHcy and PAD, indicating that homocysteine was associated with PAD independently of classical vascular risk factors.

Conclusions: In conclusion, HHcy is an independent risk factor for PAD in the Chinese Han population. A prospective and randomized clinical trial of homocysteine lowering therapy in the Chinese population is needed to assess the causal nature of the relationship.

Citing Articles

Role of hyperhomocysteinemia in atherosclerosis: from bench to bedside.

Tian W, Ju J, Guan B, Wang T, Zhang J, Song L Ann Med. 2025; 57(1):2457527.

PMID: 39898976 PMC: 11792134. DOI: 10.1080/07853890.2025.2457527.

Association of plasma homocysteine with peripheral arterial disease in the hypertensive adults: A cross-sectional study.

Yu C, Ding C, Hu L, Shi Y, Zhao P, Liu J J Clin Hypertens (Greenwich). 2024; 26(3):286-294.

PMID: 38375979 PMC: 10918742. DOI: 10.1111/jch.14766.

Association between serum uric acid and homocysteine levels among adults in the United States: a cross-sectional study.

Wang J, Zhou J, Shao Z, Chen X, Yu Z, Zhao W BMC Cardiovasc Disord. 2023; 23(1):599.

PMID: 38066416 PMC: 10704836. DOI: 10.1186/s12872-023-03586-0.

Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis.

Yuan D, Chu J, Lin H, Zhu G, Qian J, Yu Y Front Cardiovasc Med. 2023; 9:1109445.

PMID: 36727029 PMC: 9884709. DOI: 10.3389/fcvm.2022.1109445.

Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis.

Wang H, Wu P, Jiang D, Zhang H, Zhang J, Zong Y Eur J Med Res. 2022; 27(1):261.

PMID: 36411481 PMC: 9677707. DOI: 10.1186/s40001-022-00870-1.

References

Kumbhani D, Steg P, Cannon C, Eagle K, Smith Jr S, Goto S . Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35(41):2864-72. PMC: 4216432. DOI: 10.1093/eurheartj/ehu080. View

Taylor Jr L, DeFrang R, Harris Jr E, Porter J . The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991; 13(1):128-36. DOI: 10.1067/mva.1991.24913. View

Gaikwad N . Mass spectrometry evidence for formation of estrogen-homocysteine conjugates: estrogens can regulate homocysteine levels. Free Radic Biol Med. 2013; 65:1447-1454. DOI: 10.1016/j.freeradbiomed.2013.07.041. View

Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

Pradhan A, Shrivastava S, Cook N, Rifai N, Creager M, Ridker P . Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008; 117(6):823-31. DOI: 10.1161/CIRCULATIONAHA.107.719369. View

Liu J, Zuo S, Li Y, Jia X, Jia S, Zhang T . Hyperhomocysteinaemia is an independent risk factor of abdominal aortic aneurysm in a Chinese Han population. Sci Rep. 2016; 6:17966. PMC: 4750057. DOI: 10.1038/srep17966. View

Brown L, Baranowski M, Wang Y, Schrey A, Lenz T, Taverna S . Using S-adenosyl-L-homocysteine capture compounds to characterize S-adenosyl-L-methionine and S-adenosyl-L-homocysteine binding proteins. Anal Biochem. 2014; 467:14-21. PMC: 4315328. DOI: 10.1016/j.ab.2014.08.013. View

Cheng S, Ting A, Wong J . Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg. 1997; 11(3):217-23. DOI: 10.1007/s100169900037. View

Goodman J, Jensen L, He P, Yager J . Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. Pharmacogenetics. 2002; 12(7):517-28. DOI: 10.1097/00008571-200210000-00003. View

10.

Aboyans V, Criqui M, Abraham P, Allison M, Creager M, Diehm C . Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012; 126(24):2890-909. DOI: 10.1161/CIR.0b013e318276fbcb. View

11.

Kullo I, Rooke T . CLINICAL PRACTICE. Peripheral Artery Disease. N Engl J Med. 2016; 374(9):861-71. DOI: 10.1056/NEJMcp1507631. View

12.

Ueland P, Refsum H . Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989; 114(5):473-501. View

13.

Lonn E, Yusuf S, Arnold M, Sheridan P, Pogue J, Micks M . Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354(15):1567-77. DOI: 10.1056/NEJMoa060900. View

14.

Fowkes F, Rudan D, Rudan I, Aboyans V, Denenberg J, McDermott M . Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901):1329-40. DOI: 10.1016/S0140-6736(13)61249-0. View

15.

Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson J . Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170(18):1622-31. DOI: 10.1001/archinternmed.2010.348. View

16.

Khandanpour N, Loke Y, Meyer F, Jennings B, Armon M . Homocysteine and peripheral arterial disease: systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2009; 38(3):316-22. DOI: 10.1016/j.ejvs.2009.05.007. View

17.

Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B . Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990; 81(1):51-60. DOI: 10.1016/0021-9150(90)90058-q. View

18.

Ridker P, Stampfer M, Rifai N . Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001; 285(19):2481-5. DOI: 10.1001/jama.285.19.2481. View

19.

Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman R . Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015; 313(13):1325-35. DOI: 10.1001/jama.2015.2274. View

20.

Savage D, Lindenbaum J, Stabler S, Allen R . Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994; 96(3):239-46. DOI: 10.1016/0002-9343(94)90149-x. View